

Heather Boyce¹, Dajun Sun¹, Minori Kinjo¹, Saeid Raofi¹, Mitchell Frost¹, Markham Luke¹, Myong-Jin Kim¹, Robert Lionberger¹, Brad Vince², Debra Kelsh², Zhichuan Li¹ ¹Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD 20993 ²Altasciences/Vince & Associates Clinical Research Inc., Overland Park, KS 66212

Introduction

In this study, we evaluated the pharmacokinetics (PK) of nasally insufflated milled oxycodone hydrochloride (HCl) extended-release (ER) abuse deterrent (AD) products characterized by different particle size and excipient [release-controlling polymer polyethylene oxide (PEO) + inactive material] amount and assessed the effect of these variables on the bioavailability of oxycodone. The objectives of this study were:
 1. To assess the PK (C_{max} , T_{max} , AUC_{0-1} and $pAUC_{0-3}$, $pAUC_{0-4}$ as supportive) and safety of oxycodone HCl ER AD product milled to two different sizes compared to milled oxycodone HCl immediate-release (IR) product following intranasal insufflation in recreational opioid users when administered under a naltrexone block.
 2. To assess the excipient to drug (oxycodone HCl) ratio (EDR) on nasal bioavailability.

Methods

Study Design. A single center, randomized, open-label, single-dose, 4-sequence, 4-period, 4-treatment crossover, phase 1 study under a fasting stage (Table 1).

Treatment. Oxycodone ER and IR tablets (purchased through Purdue University Pharmacy) were finely or coarsely milled to a targeted particle size range of 106-500 μ m or 500-1000 μ m, respectively, using good manufacturing practices (GMP) (Table 2), Treatments A, B, and C contain PEO while D does not. Tablets were milled and packaged in the GMP facility then shipped to the clinical site for dosing.

Subjects. Healthy males and females aged between 18-55 with history of recreational opioid use defined by non-therapeutic usage on >10 occasions in their lifetime and at least one use in 12 weeks prior to screening, and with insufflation drug use experience (Table 3). Subjects were excluded if physically dependent on opioids demonstrated by failed naloxone challenge (Clinical Opiate Withdraw Scale >5).

Assessment. The subject-rated Ease of Snorting Visual Analogue Scale (ES-VAS) was conducted as a 100-point VAS answering the question, "Snorting this drug was", where 0 = "Very easy" and 100 = "Very difficult". Subject-Rated Assessment of Intranasal Irritation (SRAII) was administered through 8 hours post-dose on the 5-point scale (0 = No problem to 5 = Very Severe Problem). Ratings were based on 5 categories: Burning; Need to blow nose; Runny nose; Facial pain/pressure and Nasal congestion.

Ethics. This study was approved by the MidLands Independent Review Board (Overland Park, KS) and by the Research Involving Human Subjects Committee at the US FDA (Silver Spring, MD) and was conducted under an investigational new drug application.

Bioanalytical. Blood samples were collected in K_2 EDTA tubes, and were stored frozen until analysis. Plasma samples were assayed for oxycodone using a validated HPLC method with MS/MS detection. The lower limit of quantitation and upper limit of quantitation were 0.2 ng/mL and 100.0 ng/mL, respectively.

Statistics. Bioequivalence: two-sided 90% confidence interval of the ratio of geometric means (GM) for C_{max} , AUC_{0-1} and supportive parameters $pAUC_{0-3}$, $pAUC_{0-4}$ based on ln-transformed data.

$$EDR \text{ after milling} = \frac{\text{Recovered total milled tablet mass} - \text{Recovered drug amount}}{\text{Recovered drug amount}}$$

Table 1. Study Design Summary

Period*	1	2	3	4
Day	-28 to -1	1 - 2	3	4-5
Activity	Screening	PK	Washout	PK
			6	7-8
			9	10 - 11
			PK	Discharge
			12	14 - 15
				Follow-up

Blood Draw: Pre-dose, 0.08 (5 minutes), 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose (36 h shown in Figure 1).

* Different randomization sequences (ABDC, BCAD, CDBA, DACB) used for each period

Table 2. Treatment Summary Study

Treatment	Product Type	Tablet Characteristics		Milled Tablet Characteristics			EDR
		Tablet Strength (mg)	Tablet Weight (mg)	Milled Particle Size Range	Drug Administered (mg)	Amount of Milled Tablet Snorted (mg)	
A	ER Oxycodone	30	155	106 – 500 μ m	30	237	6.9
B	ER Oxycodone	30	155	500 – 1000 μ m	30	211	6.1
C	ER Oxycodone	80	260	106 – 500 μ m	30	177	4.9
D	IR Oxycodone	30	102	106 – 500 μ m	30	104	2.4

Results

Figure 1. Oxycodone Plasma Concentration Time Profiles (Mean \pm SD)




Table 4. Treatment Summary

Parameter	Treatment-A	Treatment-B	Treatment-C	Treatment-D
C_{max} (ng*h/mL)				
mean (C.V.%)	68 (25)	47 (28)	61 (21)	81 (27)
T_{max} (h)				
median (range)	1.5 (0.5-4)	2.5 (0.75-8.0)	2.0 (0.75 – 3.5)	1.5 (0.5-1.5)
AUC_{0-1} (ng/mL)				
mean (C.V.%)	520 (104)	441 (142)	468 (118)	415 (90)

Figure 2. GM Ratio Comparisons of Primary and Supportive PK Parameters (red dotted line = bioequivalence bound, symbols = GM ratio point estimate, error line = 90% confidence interval)




Table 3. Demographics

Characteristic	41, Healthy, Recreational Opioid Users Enrolled	
	Pharmacokinetic Population	Safety Population
N	36	41
Age, y		
mean (SD)	30 (7)	31 (7)
Range	22-50	22-50
Sex, n (%)		
Male	32 (88.9)	36 (87.8)
Female	4 (11.1)	5 (12.2)
Race, n (%)		
White	10 (27.8)	15 (36.6)
Black	26 (72.2)	26 (63.4)
Body Mass Index		
mean (SD), kg/m ³	25.10 (3.65)	25.38 (3.63)

Summary of SRAII and ES-VAS

- Treatment A was associated with the highest mean and median ES-VAS scores which indicates snorting was more difficult for this treatment.
- ES-VAS increased with increased amount of powder snorted (Table 2 & Table 5).
- The most number of irritations were reported at 0.25 h post-dose; 2/3 of subjects reported no issues over the entire time course.
- The least number of irritations were reported with Treatment-D (most by Treatment-C) and were mostly resolved by 2 h.
- Of the 113 Treatment emergent adverse events reported by 32 subjects, 5 were moderate in severity, and no serious adverse events were reported.

Table 5. Summary of ES-VAS

Statistics	Treatment-A	Treatment-B	Treatment-C	Treatment-D
Mean (SD)	28.1 (26.0)	24.7 (27.1)	20.7 (23.8)	8.1 (11.8)
Median	26.00	16.00	11.00	3.00
Range	0.0 - 82.0	0.0 - 94.0	0.0 - 74.0	0.0 - 51.0

Summary of Particle Size and EDR Effect

- EDR did not have an effect on PK at 106 – 500 μ m (Figure 2, C/A) when ranged from 4.9 to 6.9. Treatment A and C were BE.
- Particle size had an effect on how fast and the extent to which drug was absorbed (Figure 2, A/B).
- 1. Product milled to 500-1000 μ m (Treatment B) delayed T_{max} and lowered C_{max} in comparison to finely milled product (Treatment A, C) (Figure 1 & Table 4).
- 2. Although A & C include control release polymer PEO, when finely milled to 106 to 500 μ m the GM ratios were similar to milled IR product with respect to key PK parameters (C_{max} , AUC_{0-1}) and supportive PK parameters ($pAUC_{0-3}$, $pAUC_{0-4}$) (Figure 2, A/D & C/D). This indicates particle size was more significant than EDR in affecting nasal bioavailability.
- Although Treatment A and C were BE, Treatment C appeared to exhibit lower C_{max} , longer T_{max} , lower overall exposure (AUC_{0-1}) as well as lower exposure after snorting ($pAUC_{0-3}$, $pAUC_{0-4}$) than Treatment A (Figure 2 & Table 4). The amount of material snorted may have influenced this trend (Table 2). For instance, Treatment A had the highest exposure, most likely a combination of high EDR, 25% more material snorted and fine particle size which may have allowed for longer residence time in the nasal mucosa with increased nasal bioavailability.

Conclusions

This study demonstrated that when AD oxycodone ER tablets (30 mg and 80 mg) were milled to a particle size between 106-500 μ m, the PK exhibited similar C_{max} and median t_{max} to that of an IR product with similar particle size range. However, milling to a range of 500-1000 μ m delayed t_{max} and lowered the C_{max} when compared to the IR product. The EDR of ER oxycodone product did not have an impact on intranasal PK when finely milled to a size between 106-500 μ m, however, it is unknown if EDR has an effect on PK at 500 – 1000 μ m. The treatment emergent adverse events reported were mostly mild and directly related to local irritation from insufflation. There were no serious adverse events reported.

Disclaimer & Acknowledgements

This study was funded through FDA contract HHSF223201510138C to Vince and Associates Clinical Research Inc. Views expressed in this poster do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government. The authors would like to acknowledge Tonglei Li and Zhengjie Meng of Purdue University for producing the treatments used in this study.